


Stabilis



Topotecan



Noms commerciaux

| | |
|------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Acumil | Mexique |
| Camtoop | Mexique |
| Cantop | Inde |
| Hycamtin | Allemagne, Arabie Saoudite, Australie, Autriche, Belgique, Brésil, Canada, Chili, Colombie, Danemark, Egypte, Emirats Arabes Unis, Equateur, Espagne, Etats Unis d'Amérique, Finlande, France, Grande Bretagne, Grèce, Hongrie, Irlande, Islande, Italie, Japon, Luxembourg, Malaisie, Norvège, Pays bas, Pologne, Portugal, Suède, Suisse, Turquie, Vénézuëla |
| Oncotecan | Colombie, Equateur |
| Potactasol | Allemagne, Argentine, Belgique, Norvège, Roumanie |
| Tekan L | Turquie |
| Topodria | Colombie |
| Topokebir | Argentine, Pérou |
| Toposec | Pérou |
| Topotecan | Allemagne, Belgique, Canada, Colombie, Espagne, Grande Bretagne, Norvège, Pérou, Roumanie |
| Topotel | Egypte |
| Toranex | Mexique |
| Tpopoxin | Turquie |
| Viatopin | Hongrie |



Stabilité des solutions

| | | 1 mg/ml | 2-8°C | | 48 | | | 753 |
|--|--|---------|-------|--|----|--|--|------|
| | | 1 mg/ml | 2-8°C | | 28 | | | 1425 |
| | | 1 mg/ml | 25°C | | 48 | | | 753 |
| | | 1 mg/ml | 25°C | | 28 | | | 1274 |
| | | 1 mg/ml | 25°C | | 28 | | | 1425 |

| | | | | | | | | |
|--|--|--------------------|-----------|--|----|--|--|------|
| | | 1 mg/ml | 4°C | | 28 | | | 1274 |
| | | 1 mg/ml | 5°C | | 28 | | | 823 |
| | | 0,05 mg/ml | 23-24°C | | 24 | | | 1075 |
| | | 0,05 mg/ml | 5°C | | 7 | | | 1075 |
| | | 0,01 >> 0,05 mg/ml | 2-8°C | | 28 | | | 1425 |
| | | 0,01 >> 0,05 mg/ml | 25°C | | 28 | | | 1425 |
| | | 0,025 mg/ml | 23°C-24°C | | 24 | | | 1075 |
| | | 0,025 mg/ml | 5°C | | 7 | | | 1075 |
| | | 0,05 mg/ml | 23-24°C | | 24 | | | 1075 |
| | | 0,05 mg/ml | 5°C | | 7 | | | 1075 |
| | | 0,05 & 0,025 mg/ml | 25°C | | 28 | | | 1274 |
| | | 0,05 & 0,025 mg/ml | 4°C | | 28 | | | 1274 |
| | | 0,01 mg/ml | 25°C | | 7 | | | 1274 |
| | | 0,05 mg/ml | 23-24°C | | 24 | | | 1075 |
| | | 0,05 mg/ml | 5°C | | 7 | | | 1075 |
| | | 0,01 & 0,05 mg/ml | 25°C | | 21 | | | 1274 |
| | | 0,01 & 0,05 mg/ml | 4°C | | 21 | | | 1274 |
| | | 0,01 >> 0,05 mg/ml | 2-8°C | | 28 | | | 1425 |
| | | 0,01 >> 0,05 mg/ml | 25°C | | 28 | | | 1425 |



Stabilité en mélange















| | | 0,05 mg/ml | 20°C-25°C | | Palonosetron hydrochloride : 25 µg/ml | 4 | | 1976 |
|--|--|-------------|-----------|--|-------------------------------------------------|---|--|------|
| | | 0,028 mg/ml | 20°C-23°C | | Carboplatin : 0,45 mg/ml | 4 | | 1026 |
| | | 0,028 mg/ml | 20°C-23°C | | Cimetidine hydrochloride : 2,88 mg/ml | 4 | | 1026 |
| | | 0,028 mg/ml | 20°C-23°C | | Cisplatine : 0,084 mg/ml | 4 | | 1026 |
| | | 0,028 mg/ml | 20°C-23°C | | Cyclophosphamide : 10 mg/ml | 4 | | 1026 |
| | | 0,028 mg/ml | 20°C-23°C | | Doxorubicin hydrochloride : 1 mg/ml | 4 | | 1026 |
| | | 0,028 mg/ml | 20°C-23°C | | Etoposide : 0,2 mg/ml | 4 | | 1026 |
| | | 0,028 mg/ml | 20°C-23°C | | Granisetron hydrochloride : 0,01 mg/ml | 4 | | 1026 |
| | | 0,028 mg/ml | 20°C-23°C | | Ifosfamide : 7,14 mg/ml | 4 | | 1026 |
| | | 0,028 mg/ml | 20°C-23°C | | Methylprednisolone sodium succinate : 1,2 mg/ml | 4 | | 1026 |

| | | | | | | | | |
|--|--|-------------|-----------|--|-------------------------------------------|---|--|------|
| | | 0,028 mg/ml | 20°C-23°C | | Metoclopramide hydrochloride : 0,86 mg/ml | 4 | | 1026 |
| | | 0,028 mg/ml | 20°C-23°C | | Ondansetron hydrochloride : 0,24 mg/ml | 4 | | 1026 |
| | | 0,028 mg/ml | 20°C-23°C | | Paclitaxel : 0,27 mg/ml | 4 | | 1026 |
| | | 0,028 mg/ml | 20°C-23°C | | Prochlorperazine edysilate : 0,096 mg/ml | 4 | | 1026 |
| | | 0,028 mg/ml | 20°C-23°C | | Vincristine sulfate : 0,5 mg/ml | 4 | | 1026 |



Compatibilités

| | Topotecan : 0.056 mg/ml Carboplatin : 0.9 mg/ml | | 1026 | |
|--|----------------------------------------------------------------------------|---------------------------------------------------------------------|------|------|
| | Topotecan : 0.056 mg/ml Cimetidine hydrochloride : 5.76 mg/ml | | 1026 | |
| | Topotecan : 0.056 mg/ml Cisplatin : 0.168 mg/ml | | 1026 | |
| | Topotecan : 0.056 mg/ml Cyclophosphamide : 20 mg/ml | | 1026 | |
| | | Topotecan : 0.056 mg/ml Dexamethasone sodium phosphate : 4 mg/ml | | 1026 |
| | Topotecan : 0.056 mg/ml Dexamethasone sodium phosphate : 4 mg/ml | | 1026 | |
| | Topotecan : 0.056 mg/ml Doxorubicin hydrochloride : 2 mg/ml | | 1026 | |
| | Topotecan : 0.056 mg/ml Etoposide : 0.4 mg/ml | | 1026 | |
| | Topotecan : 0.056 mg/ml Fluorouracil : 50 mg/ml | | 1026 | |
| | | Topotecan : 0.056 mg/ml Fluorouracil : 50 mg/ml | | 1026 |
| | Topotecan : 0.1 mg/ml Gemcitabine hydrochloride : 10 mg/ml | | 1423 | |
| | Topotecan : 0.056 mg/ml Granisetron hydrochloride : 0.02 mg/ml | | 1026 | |
| | Topotecan : 0.056 mg/ml Ifosfamide : 14.28 mg/ml | | 1026 | |
| | Topotecan : 0.056 mg/ml Methylprednisolone sodium succinate : 2.4 mg/ml | | 1026 | |
| | Topotecan : 0.056 mg/ml Metoclopramide hydrochloride : 1.72 mg/ml | | 1026 | |
| | | Topotecan : 0.056 mg/ml Mitomycin : 0.084 mg/ml | | 1026 |
| | Topotecan : 0.056 mg/ml Ondansetron hydrochloride : 0.48 mg/ml | | 1026 | |
| | Topotecan : 0,1 mg/ml Oxaliplatin : 0,5 mg/ml | | 1662 | |
| | Topotecan : 0.056 mg/ml Paclitaxel : 0.54 mg/ml | | 1026 | |

| | | | | |
|-----------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|---------------------------------------------------------------------------|------------------------------------------------------------------------------------|------|
| |  | Topotecan : 0,1 mg/ml Palonosetron hydrochloride : 50 µg/ml |  | 1976 |
|  |  | Topotecan : 0.1 mg/ml Pemetrexed disodium : 20 mg/ml |  | 1953 |
| |  | Topotecan : 0.056 mg/ml Prochlorperazine edysilate : 0.192 mg/ml |  | 1026 |
| |  | Topotecan : 0.056 mg/ml Ticarcillin / clavulanic acid : 47.6/1.6 mg/ml |  | 1026 |
|  |  | Topotecan : 0.056 mg/ml Ticarcillin / clavulanic acid : 47.6/1.6 mg/ml |  | 1026 |
| |  | Topotecan : 0.056 mg/ml Vincristine sulfate : 1 mg/ml |  | 1026 |



Voie d'administration











































Bibliographie

| | Type | Source |
|------|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 753 | Laboratoire | Topotecan (Topotecan Hospira®) - Summary of Product Characteristics Hospira 2016 |
| 823 | Revue | Patel K, Craig SB, McBride MG, Palepu NR. Microbial inhibitory properties and stability of topotecan hydrochloride injection. Am J Health-Syst Pharm 1998 ; 55: 1584-1587. |
| 1026 | Revue | Mayron D, Gennaro AR. Stability and compatibility of topotecan hydrochloride with selected drugs. Am J Health-Syst Pharm 1999 ; 56: 875-881. |
| 1075 | Revue | Craig SB, Bhatt UH, Patel K. Stability and compatibility of topotecan hydrochloride for injection with common infusion solutions and containers. J Pharm Biomed Anal 1997 ; 16: 199-205. |
| 1274 | Revue | Krämer I, Thiesen J. Pharmazeutische aspekte von topotecan-infusionen. TAP Pharmazeutische Zeitung 1997 ; 31: 30-33. |
| 1423 | Revue | Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hydrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518. |
| 1425 | Revue | Krämer I, Thiesen J. Stability of topotecan infusion solutions in polyvinylchloride bags and elastomeric portable infusion devices. J Oncol Pharm Practice 1999 ; 5: 75-82. |
| 1662 | Revue | Trissel LA, Saenz CA, Ingram DS, Ogundele AB. Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs. J Oncol Pharm Practice 2002 ; 8: 33-37. |
| 1953 | Revue | Trissel LA, Saenz CA, Ogundele AB, Ingram DS. Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2004 ; 61: 2289-2293. |

| | | |
|------|-------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1976 | Revue | Trissel LA, Xu QA. Physical and chemical stability of palonosetron hydrochloride with topotecan hydrochloride and irinotecan hydrochloride during simulated Y-site administration. Int J Pharm Compound 2005 ; 9, 3: 238-241. |
|------|-------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|



Dictionnaire

| | |
|-------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------|
|  Anticancéreux |  Injectable |
|  Noms commerciaux |  Stabilité des solutions |
|  Contenant |  Molécule |
|  Concentration |  Température |
|  Conservation |  Durée de stabilité |
|  Biosimilaire |  Données conflictuelles |
|  Bibliographie |  Verre |
|  Eau pour préparation injectable |  Non précisée |
|  Heure |  A l'abri de la lumière |
|  Jour |  NaCl 0,9% ou glucose 5% |
|  Lumière |  Polyvinyl chlorure |
|  Chlorure de sodium 0,9% |  Polyoléfine |
|  Elastomère en polyisoprène |  Stabilité en mélange |
|  Solvant |  Molécule |
|  Glucose 5% |  Non précisé |
|  Compatibilités |  Compatible |
|  Turbidité immédiate |  Incompatible |
|  Changement de couleur |  Instabilité chimique |
|  Voie d'administration |  Perfusion intraveineuse |
|  Bibliographie |  Dictionnaire |